Trastuzumab emtansine
A drug used in cancer treatment
| Trastuzumab emtansine | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Trastuzumab emtansine, also known as ado-trastuzumab emtansine, is a monoclonal antibody used in the treatment of HER2-positive breast cancer. It is a conjugate of the monoclonal antibody trastuzumab and the cytotoxic agent DM1, a derivative of maytansine.
Mechanism of action[edit | edit source]
Trastuzumab emtansine works by targeting the HER2 receptor, which is overexpressed in some breast cancer cells. The trastuzumab component binds to the HER2 receptor, inhibiting the proliferation of cancer cells. Once bound, the conjugate is internalized by the cancer cell, where the emtansine component is released, disrupting microtubule function and leading to cell death.
Clinical use[edit | edit source]
Trastuzumab emtansine is primarily used for the treatment of patients with HER2-positive metastatic breast cancer who have previously received trastuzumab and a taxane. It is administered intravenously and has been shown to improve progression-free survival and overall survival in clinical trials.
Side effects[edit | edit source]
Common side effects of trastuzumab emtansine include fatigue, nausea, muscle pain, and thrombocytopenia. Serious side effects can include liver toxicity, heart problems, and lung disease. Patients are monitored for these adverse effects during treatment.
Approval and regulation[edit | edit source]
Trastuzumab emtansine was approved by the FDA in 2013 for the treatment of HER2-positive metastatic breast cancer. It is marketed under the brand name Kadcyla.
Research and development[edit | edit source]
Ongoing research is exploring the use of trastuzumab emtansine in other types of HER2-positive cancers and in combination with other therapies. Clinical trials are investigating its efficacy in earlier stages of breast cancer and in combination with other targeted therapies.
Related pages[edit | edit source]
References[edit | edit source]
Trastuzumab emtansine[edit | edit source]
Trastuzumab emtansine
Emtansine mab structure
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
